RLYB
Rallybio Corp
NASDAQ · Healthcare · Biotechnology · US
$17.19
+0.17%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$1.44
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$1.09
- EPS estimate
- -$1.28
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +6.1%
- Revenue beats (12Q)
- 3
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$1.28 | -$1.09 | Beat 14.84% | — |
| May 13, 2026 | -$1.20 | -$1.46 | Miss -21.67% | $212.0K |
| Nov 6, 2025 | -$0.25 | -$0.14 | Beat 44.00% | $212.0K |
| Aug 7, 2025 | -$0.20 | -$0.22 | Miss -12.82% | $212.0K |
| May 8, 2025 | -$0.21 | -$0.21 | In line | $212.0K |
| Mar 13, 2025 | -$0.27 | -$0.25 | Beat 7.41% | $38.0K |
| Nov 7, 2024 | -$0.36 | -$0.26 | Beat 27.78% | $299.0K |
| Aug 8, 2024 | -$0.42 | -$0.37 | Beat 11.90% | $299.0K |
| May 9, 2024 | -$0.50 | -$0.47 | Beat 6.00% | — |
| Mar 12, 2024 | -$0.44 | -$0.50 | Miss -13.64% | $228.0K |
| Nov 9, 2023 | -$0.51 | -$0.45 | Beat 11.76% | — |
| Mar 6, 2023 | -$0.63 | -$0.46 | Beat 26.98% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026